Article
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology - 1 Aug 1998
Miller M D, Lamy P D, Fuller M D, Mulato A S, Margot N A, Cihlar T, Cherrington J M
Abstract excerpt
Adefovir dipivoxil [9-(2-(bispivaloyloxymethyl)phosphonylmethoxyethyl)adenine (bis-POM PMEA)], an oral prodrug of adefovir (PMEA), is currently in phase III clinical testing for the treatment of human immunodeficiency virus-1 (HIV-1) infection. Previous in vitro experiments have shown that HIV-1 recombinant viruses expressing either a K65R or a K70E mutation in reverse transcriptase (RT) have reduced sensitivity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.